Rucaparib一线维持治疗晚期卵巢癌:ATHENA-MONO研究5年随访OS、PFS与安全性
ATHENA-MONO/GOG-3020/ENGOT-ov45 III期随机双盲安慰剂对照研究评估Rucaparib一线维持治疗晚期卵巢癌的长期疗效与安全性。中位随访约59个月,HRD人群invPFS 31.4 vs 12.0个月(HR 0.52,95%CI 0.35-0.76),ITT人群20.2 vs 9.2个月(HR 0.53,95%CI 0.42-0.69)。ITT人群OS未成熟(成熟度35%),中位OS在Rucaparib组未达到,安慰剂组46.2个月(95%CI 34.6-未达到),HR 0.83(95%CI 0.58-1.17)。
要点
- Rucaparib一线维持显著延长HRD和ITT人群的invPFS,获益持久。
- ITT人群OS数据未成熟,HR 0.83(95%CI 0.58-1.17),中位OS未达到 vs 46.2个月。
- 安全性与此前主要分析一致,未出现新安全信号。
核心结论
- Rucaparib单药一线维持治疗为晚期卵巢癌患者(无论HRD状态)提供显著且持久的长期获益。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照III期ATHENA-MONO/GOG-3020/ENGOT-ov45研究(NCT03522246)。
- 患者按4:1随机接受口服Rucaparib+静脉安慰剂或口服+静脉安慰剂。
- 分层因素为HRD分类(BRCA突变和杂合性缺失状态)、化疗后残留病灶和手术时机。
- 主要终点为研究者评估的PFS(invPFS),在HRD和ITT人群中分析;OS和安全性为次要终点。
主要发现
- 中位invPFS随访约59个月,Rucaparib组HRD人群n=185,ITT人群n=427;安慰剂组HRD人群n=49,ITT人群n=111。
- HRD人群invPFS:Rucaparib组31.4个月 vs 安慰剂组12.0个月,HR 0.52(95%CI 0.35-0.76)。
- ITT人群invPFS:Rucaparib组20.2个月 vs 安慰剂组9.2个月,HR 0.53(95%CI 0.42-0.69)。
- ITT人群 interim OS未成熟(成熟度35%),中位OS在Rucaparib组未达到,安慰剂组46.2个月(95%CI 34.6-未达到),HR 0.83(95%CI 0.58-1.17)。
- ITT人群TFST中位23.6 vs 12.1个月,PFS2中位35.1 vs 26.9个月,Rucaparib组均更长。
关键数值与推荐
- Rucaparib组34.6%患者完成24个月治疗上限,安慰剂组为17.3%。
- 截至2025年5月5日,40.0%的Rucaparib组患者仍在研究中并处于长期随访。
临床怎么用
- Rucaparib可作为晚期卵巢癌一线维持治疗选择,无论HRD状态均可获益。
- 治疗时长上限为24个月,部分患者可完成全程治疗。
- 长期随访中安全性一致,支持临床持续使用。
局限性
- OS数据未成熟,需更长随访确认最终OS获益。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report the long-term efficacy and safety from the multicenter, randomized, double-blind, placebo-controlled, phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 (NCT03522246) study of first-line rucaparib maintenance for advanced ovarian cancer. PATIENTS AND METHODS: Patients were randomized 4 : 1 to oral rucaparib + intravenous (i.v.) placebo or oral + i.v. placebo. Stratification factors were homologous recombination deficiency (HRD; BRCA mutation and loss of heterozygosity status) classification, residual disease post-chemotherapy, and surgical timing. The primary endpoint was investigator-assessed progression-free survival (invPFS) in HRD and intent-to-treat (ITT) populations. Overall survival (OS) and safety were secondary endpoints. Second event of progression (PFS2) and time to first subsequent treatment (TFST) were exploratory. Interim OS and final safety analyses data cut-off was 9 March 2023. Updated invPFS, PFS2, and TFST analyses data cut-off was 5 May 2025. RESULTS: Median invPFS follow-up was ∼59 months for both rucaparib (HRD, n = 185; ITT, n = 427) and placebo (HRD, n = 49; ITT, n = 111). invPFS was significantly longer with rucaparib versus placebo in the HRD [31.4 versus 12.0 months; hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.35-0.76] and ITT (20.2 versus 9.2 months; HR 0.53, 95% CI 0.42-0.69) populations. Interim OS was immature (OS maturity: ITT 35%) with the median (95% CI) OS not reached with rucaparib and 46.2 (34.6-not reached) months with placebo for the ITT population (HR 0.83, 95% CI 0.58-1.17). ITT TFST (median 23.6 versus 12.1 months) and PFS2 (35.1 versus 26.9 months) were longer with rucaparib versus placebo. Overall, 34.6% of patients receiving rucaparib completed the 24-month treatment cap versus 17.3% receiving placebo. As of 5 May 2025, 40.0% of patients on rucaparib were still on study and in long-term follow-up. Safety remained consistent with the primary analysis. CONCLUSIONS: Rucaparib monotherapy provides significant and durable long-term benefit as first-line maintenance for patients with advanced ovarian cancer with and without HRD.
引用
- Kristeleit RS, Ghamande S, Lisyanskaya A, et al. Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study. Ann Oncol. 2025. PMID: 41115469. doi:10.1016/j.annonc.2025.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。